Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2110-2120

  Bey, Erik A ^a   Reinicke, Kathryn E ^b   Srougi, Melissa C ^b   Varnes, Marie ^b   Anderson, Vernon E ^b   Pink, John J ^b   Li, Long Shan ^c   Patel, Malina ^c   Cao, Lifen ^c   Moore, Zachary ^c   Rommel, Amy ^c   Boatman, Michael ^a   Lewis, Cheryl ^c   Euhus, David M ^c   Bornmann, William G ^d   Buchsbaum, Donald J ^e   Spitz, Douglas R ^f   Gao, Jinming ^c   Boothman, David A ^c  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOPTOSIS INDUCING FACTOR; BETA LAPACHONE; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROGEN PEROXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN MSH2; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SUPEROXIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LETHALITY; NITROSYLATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SINGLE STRANDED DNA BREAK; SOLID TUMOR;

BREAST NEOPLASMS; CATALASE; DNA BREAKS, SINGLE-STRANDED; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN PEROXIDE; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; NECROSIS; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES;

EID: 84885647211     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0962     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60: 277-300.
2. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15: 7479-91.
3. Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. MayoClin Proc 2009;84: 533-45.
4. May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res 2011;13:202.
5. O'Brien CS, Howell SJ, Farnie G, Clarke RB. Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia 2009;14: 45-54.
6. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003;22: 7414-30.
7. Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1- induced programmed necrosis. Cancer Res 2012;72: 3038-47.
8. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004;18: 1272-82.
9. Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002;297: 259-63.
10. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006;20: 1-15.
11. Marin A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuela JM, Idoate MA, et al. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Br J Cancer 1997;76: 923-9.
12. Dong Y, Bey EA, Li LS, Kabbani W, Yan J, Xie XJ, et al. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation. Cancer Res 2010;70: 8088-96.
13. Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW, Cullen JJ. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 2005;43: 215-24.
14. Boothman DA, Trask DK, Pardee AB. Inhibition of potentially lethal DNA damage repair in human tumor cells by b-lapachone, an activator of topoisomerase I. Cancer Res 1989;49: 605-12.
15. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of b-lapachone cytotoxicity. J Biol Chem 2000;275: 5416-24.
16. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in b-lapachone-mediated cell death. J Biol Chem 2001;276: 19150-9.
17. Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calciumdependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair. J Biol Chem 2006;281: 33684-96.
18. Bey EA, Bentle MS, Reinicke KE, Dong Y, Yang CR, Girard L, et al. An NQO1- and PARP-1-mediated cell death pathway induced in nonsmall- cell lung cancer cells by b-lapachone. Proc Natl Acad Sci U S A 2007;104: 11832-7.
19. Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of b-lapachone for pancreatic cancer therapy. Clin Cancer Res 2011;17: 275-85.
20. Bentle MS, Bey EA, Dong Y, Reinicke KE, Boothman DA. New tricks for old drugs: the anticarcinogenic potential ofDNA repair inhibitors. J Mol Histol 2006;37: 203-18.
21. Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, et al. Development of b-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res 2005;11: 3055-64.
22. Zhao W, Spitz DR, Oberley LW, Robbins ME. Redox modulation of the pro-fibrogenic mediator plasminogen activator inhibitor-1 following ionizing radiation. Cancer Res 2001;61: 5537-43.
23. Goshe MB, Anderson VE. Hydroxyl radical-induced hydrogen/deuterium exchange in amino acid carbon-hydrogen bonds. Radiat Res 1999;151: 50-8.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193: 265-75.
25. Tagliarino C, Pink JJ, Reinicke KE, Simmers SM, Wuerzberger-Davis SM, Boothman DA. Mu-calpain activation in b-lapachone-mediated apoptosis. Cancer Biol Ther 2003;2: 141-52.
26. Casiano CA, Ochs RL, Tan EM. Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ 1998;5: 183-90.
27. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 2004;25: 259-64.
28. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, et al. Snitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 2005;7: 665-74.
29. Lee H, Park MT, Choi BH, Oh ET, Song MJ, Lee J, et al. Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by b-lapachone treatment. PLoS One 2011;6:e21533.
30. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 2005;280: 6447-54.
31. Colell A, Green DR, Ricci JE. Novel roles for GAPDH in cell death and carcinogenesis. Cell Death Differ 2009;16: 1573-81.
32. Mohr S, Stamler JS, Brune B. Posttranslational modification of glyceraldehyde- 3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment. J Biol Chem 1996;271: 4209-14.
33. Sirover MA. Minireview. Emerging new functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. Life Sci 1996;58: 2271-7.
34. Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehyde- 3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci 2001;114: 1643-53.
35. Alexander NM. Catalase inhibition by normal and neoplastic tissue extracts. J Biol Chem 1957;227: 975-85.
36. Bannister WH, Bannister JV. Factor analysis of the activities of superoxide dismutase, catalase and glutathione peroxidase in normal tissues and neoplastic cell lines. Free Radic Res Commun 1987;4: 1-13.
37. Sihto H, Lundin J, Lundin M, Lehtimaki T, Ristimaki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res 2011;13:R87.
38. Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomaki K, et al. NQO1 expression correlates inversely with NFkB activation in human breast cancer. Breast Cancer Res Treat 2012;132: 955-68.
39. Chiu SM, Oleinick NL. Dissociation of mitochondrial depolarization from cytochrome c release during apoptosis induced by photodynamic therapy. Br J Cancer 2001;84: 1099-106.
40. Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, et al. Efficacy of b-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther 2005;4: 95-102.
41. Schonhoff CM, Matsuoka M, Tummala H, Johnson MA, Estevez AG, Wu R, et al. S-nitrosothiol depletion in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2006;103: 2404-9.